Pharmaceutical Industry News 10 December 2025

Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb Company (NYSE: BMY) is back in the spotlight on December 16, 2025, with the stock trading around $54.29, up roughly 3.6% on the session as optimism builds around Wall Street upgrades, a newly announced dividend increase, and a

16 December 2025

Analyst Ratings·Dividends·Investing·Pharmaceutical Industry·Stock Market

Bristol-Myers Squibb (BMY) Stock After Hours: BofA Upgrade Sparks a Rally — What to Know Before the Market Opens Dec. 16, 2025

Bristol-Myers Squibb Company (NYSE: BMY) is ending Monday’s session in the spotlight after a sharp, analyst-driven move that pushed the pharma giant higher into the close — and kept the shares firm in extended trading. After the closing bell on

16 December 2025

After Hours Trading·Investing·Market Analysis·Pharmaceutical Industry·Stock Market

Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025)

Pfizer Inc. (NYSE: PFE) enters the new week with its stock hovering around $25.85 in early Monday trading, as investors weigh a familiar late-2025 mix: a high dividend, a rebuilding growth story after the COVID boom, and a pipeline/M&A strategy

15 December 2025

Analyst Forecasts·Dividends·Pfizer·Pharmaceutical Industry·Stock Market

Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) entered a new phase in its corporate life this month: from clinical-stage story stock to a company with an FDA-approved, commercially launchable cardiovascular product. The catalyst is CARDAMYST™ (etripamil) nasal spray, now approved in the

15 December 2025

Analyst Forecasts·FDA Approvals·Investment Insights·Pharmaceutical Industry·Stock Market News

CSL Limited Stock (ASX:CSL) Update: Hemgenix 5-Year Data, Vaccine Audit Fallout, Buyback Support — Week Ahead Outlook (Updated 14 Dec 2025)

CSL Limited shares closed Friday at A$183.93, ending a volatile week only slightly lower overall after a sharp rebound into the weekend. Investors are weighing two very different storylines at once: encouraging long-term clinical data for CSL’s hemophilia B gene

14 December 2025

Biotechnology·Investment Insights·Market Updates·Pharmaceutical Industry·Stock Analysis

Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025)

Anavex Life Sciences Corp. (NASDAQ: AVXL) is back in the spotlight on Friday, December 12, 2025, after European regulators recommended refusing marketing authorization for Blarcamesine Anavex (also known as blarcamesine / ANAVEX®2-73) in Alzheimer’s disease—an outcome that investors had been

12 December 2025

Analyst Forecasts·Biotech Stocks·Investment Updates·Pharmaceutical Industry·Stock Market News

GSK Stock News Today (Dec. 12, 2025): Arexvy EU Expansion, Blujepa FDA Approval, Analyst Forecasts and What’s Next

Published: 12 December 2025 GSK plc stock is back in focus on Friday as investors digest a fast-moving cluster of regulatory headlines across vaccines, infectious diseases and oncology—alongside ongoing buybacks and fresh consensus forecasts that map out how GSK’s revenue

12 December 2025

Analyst Insights·FDA Approvals·Investment Trends·Pharmaceutical Industry·Stock Market News

Pfizer (PFE) Stock Outlook After the November 21 FDA Win: Obesity Deals, Cost Cuts and a 6.7% Dividend Yield

As of December 11, 2025, Pfizer Inc. (NYSE: PFE) is trying to rewrite its post‑COVID story. The stock trades around $25.66 per share, after a choppy year of guidance upgrades, obesity-drug M&A, aggressive cost cuts and fresh regulatory wins in

11 December 2025

Dividend Stocks·FDA Approvals·Investment News·Pharmaceutical Industry·Stock Analysis

Wave Life Sciences (WVE) Stock on December 11, 2025: Obesity Breakthrough, 180% Rally, $350M Offering and Fresh Analyst Targets

Updated: December 11, 2025 – all figures and ratings as of publication; this article is for information only and is not investment advice. Key takeaways WVE stock today: from under‑the‑radar biotech to market spotlight Wave Life Sciences Ltd. (NASDAQ: WVE),

11 December 2025

Analyst Ratings·Biotechnology·Pharmaceutical Industry·Stock Market

Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets

Vera Therapeutics, Inc. (NASDAQ: VERA) is back center stage on December 11, 2025, as traders digest a fresh equity offering, strong late‑stage clinical data, and a newly filed Biologics License Application (BLA) for its lead drug, atacicept, in IgA nephropathy

11 December 2025

Biotech News·Investment Strategies·Market Updates·Pharmaceutical Industry·Stock Analysis

Arrowhead Pharmaceuticals (ARWR) Stock Near 52‑Week High After FDA Approval and New Alzheimer’s Trial: Latest News & Forecasts as of December 11, 2025

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has quietly turned into one of 2025’s wildest biotech comeback stories. After years as a perpetually “promising” RNA interference (RNAi) platform, the company now has: The stock price has responded in full drama mode. As of

11 December 2025

Biotechnology·FDA Approvals·Investment Analysis·Pharmaceutical Industry·Stock News

Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer Inc. (NYSE: PFE) finished a volatile Tuesday session on December 9, 2025 under pressure, then stabilized in after-hours trading as investors digested a big new obesity-drug licensing deal and fresh headlines around RSV therapies. With the next U.S. market

10 December 2025

Pfizer·Pharmaceutical Industry·Pre-Market Analysis·Stock Market

Pharmaceutical Industry News 10 December 2025 - 16 December 2025